Positive findings from full cohorts of patients with colorectal cancer enrolled in ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study are being presented in poster sessions at the Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco.

The abstracts, which will be presented at various poster sessions on Saturday, January 25, report on three TAPUR Study colorectal cancer cohorts that showed anti-tumor activity over a 16-week period. The TAPUR Study abstracts report positive results in study cohorts that expanded to include additional patients because two or more patients had a positive response (which includes stable disease).

“Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study” (abstract 22) by Kelsey A. Klute, MD, et al. found that a combination of C+V showed anti-tumor activity in heavily pre-treated CRC patients with BRAF V600E mutations.

Presentation Information:

Poster Session C: Anal and Colorectal Cancer
Saturday, January 25, 2020
Time: 6:30–7:55 AM
Location: Level 1, West Hall
Poster #: F8

“Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the TAPUR Study” (abstract 133) by Eyal Meiri, MD, et al., found that monotherapy with P showed anti-tumor activity in heavily pre-treated CRC patients with HTMB.

Presentation Information:

Poster Session C: Anal and Colorectal Cancer
Saturday, January 25, 2020
Time: 6:30–7:55 AM

Poster Walks: Anal and Colorectal Cancer
Saturday, January 25, 2020
Time: 12:30–1:15 PM
Location: Level 1, West Hall
Poster #: F19

“Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study” (abstract 132) by Ranju Gupta, MD, et al., concluded that a combination of P+T showed anti-tumor activity in heavily pre-treated CRC patients with ERBB2 amplification.

Presentation Information:

Poster Session C: Anal and Colorectal Cancer
Saturday, January 25, 2020
Time: 6:30–7:55 AM
Location: Level 1, West Hall
Poster Board #: F18

View all abstracts from the symposium and the full list of TAPUR Study patient cohort expansions and closures.

The TAPUR Study

The TAPUR Study evaluates molecularly targeted cancer drugs and collects data on clinical outcomes to learn about additional uses of these drugs outside of Food and Drug Administration (FDA)-approved indications. It also provides a clinical trial opportunity for patients with advanced cancer who have genomic alterations in their tumors that can be targeted with a TAPUR Study drug and who are no longer benefitting from standard anti-cancer treatments or for whom no acceptable standard treatment is available. There are currently eight companies providing cancer drugs at no cost to enrolled study participants.

Study participants are enrolled in cohorts of 10 based on their tumor types (e.g., an advanced solid tumor), the genomic alterations of their tumors, and the targeted drug(s) matched to those alterations in the TAPUR Study protocol. There are two stages for each cohort to enable early stopping or expansion based on treatment response. If fewer than two of 10 participants have successful outcomes at Stage I (according to the independent TAPUR Data and Safety Monitoring Board), the cohort is closed. If two or more participants have successful outcomes, the cohort is expanded to Stage II to enroll an additional 18 participants. If seven or more of 28 participants respond or have stable disease lasting at least 16 weeks, the study reports a positive efficacy signal.

There are currently nearly 120 TAPUR Study sites in 22 states and more than 1,750 participants who have received a therapy through the trial.

The TAPUR Study is registered on ClinicalTrials.gov (NCT 02693535), which includes a list of inclusion/exclusion criteria and other information. Additional information is available on the TAPUR Study website.